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BACKGROUND. Tissue microarray allows rapid and efficient evaluation of gene
expression at the protein level and of immunochemical markers. To our knowl-
edge, there has been no report of constructing cytology microarray using effusion
cell blocks and testing its utility in immunochemical marker validation.
METHODS. A total of 23 malignant effusions (primary tumor of breast [5], GI tract
[5], lung [5] and ovary [8]) were used to construct a cytology microarray so that 3
cores of 0.6 mm in diameter were taken from the original cell blocks. Antibodies
including AE1/AE3, EMA, and Ki-67 were applied to all cases, and CK7, CK20,
TTF-1, WT-1, ER, and PR antibodies were used for selected cases. The cellularity,
composition of cells, the staining pattern, and the intensity of each antibody
were compared between corresponding cell block sections and CMA cores.
RESULTS. The composition of tumor cells in the original block and the cores
(including Sections 1 and 45) on cytology microarray were similar, ranging from
5% to 90%. Immunostains of AE1/AE3 and EMA were all positive and 100% con-
cordant between the originals and cytology microarray. Similarly, CK7, CK20, ER,
PR, TTF-1, and WT-1 stained both original blocks and cytology microarray with a
high level of agreement with respect to percentage of positive cells, staining pat-
tern (cytoplasm or nuclear), and intensity. Ki-67 stain showed slightly lower con-
cordance (84%) with a few cases not in agreement because of low tumor burden
in the original block coupled with low percentage of staining by antibody.
CONCLUSIONS. Three 0.6 mm cores of cytology microarray are representative of
the original cell block with cellularity and antibody staining pattern, intensity,
and percentage. Therefore, CMA has a great potential in clinical research and
practice as it allows rapid validation of immunocytochemical markers. Cancer
(Cancer Cytopathol) 2008;114:300–6.  2008 American Cancer Society.
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A lthough tissue microarrays (TMA) have been widely used in thecancer research field for high-throughput gene expression anal-
ysis and validation of tumor markers on tissue,1-8 cytology microar-
ray (CMA) has not been tested in cytology samples for such a
purpose. In particular, the use of CMA for the purpose of marker vali-
dation or other research has not been reported. There is 1 recent
report using cytology material to construct microarray with success
but no marker testing was performed in that study.9 Cytology mate-
rial is usually presented in the form of small cellular aggregates rather
than the large tissue fragments seen in surgical pathology material.
Whether the small cell clusters in cores of CMA will be representative
of the standard section is not known. The objectives of this study are
to first validate the utility of CMA in its representation of the original
cell blocks in cell numbers and composition; and then to confirm
that immunostains on CMA can recapitulate the original section with
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several antibodies frequently used in differential diag-
nosis of some common tumors.
MATERIALS AND METHODS
The authors constructed a microarray using standard
cell blocks obtained from malignant effusions. The
original tumors were known and the subsequent
effusions were diagnosed by evaluation of morphol-
ogy and often supported with immunocytochemical
stain profile and clinical outcomes. Fresh effusions
were centrifuged and sediments were used to make
cell blocks by plasma-thrombin method. Briefly, after
decanting supernatant, several drops of plasma and
thrombin were added to the sediments to mix by
gentle vortex and the mixture was then allowed to
clot, followed by fixation with 10% buffered formalin
solution for at least 1 hour (up to 10 hours) before
being processed for embedding in paraffin block. A
total of 23 malignant effusions of primary tumor of
breast, lung, ovary, and gastrointestinal (GI) tract
(including esophageal and pancreatic carcinoma)
were used to construct a CMA so that 3 cores, each
0.6 mm in diameter, were taken from each of the ori-
ginal effusion cell blocks. Three cores were taken
TABLE 1
Lists of Antibody and Dilutions
Vendor
AE1/AE3 EMA Ki67 CK7 CK20 ER PR TTF-1 WT-1
Chemicon DAKO DAKO DAKO DAKO DAKO DAKO DAKO Cell Marque Corp
Cat# MAB 3412 M0613 M7241-01 M7018 M7019 M7047 M3569 M3575-01 80703/1 CMC788
Clone — E29 MIB-1 OV-TL 12/10 Ks20.8 1D5 PgR 636 — 6F-H2
Dilution 1:100 1:25 1:50 1:12.5 1:25 1:50 1:50 1:200 1:30
AE1/AE3 indicates cytokeratin.
FIGURE 1. Representative CMA cores stained with hematoxylin and eosin (top 2 rows) or immunostained by AE1/AE3 antibody (bottom 2 rows). Four cases
are represented with triplet cores (from right to left), representing cases with low (1 core of the first case had no cells) to moderate cellularity and moderate to
strong cytoplasmic stain by AE1/AE3.
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from areas representative of the original cell block by
aligning with spots marked on cell block hematoxylin
and eosin (H & E) slides selected by a cytopatholo-
gist (C. W. Michael). Normal tissue controls were also
included in the CMA block. In total, 84 cores consist-
ing of 5 types of control of tissues (5 3 3 5 15) and
23 malignant effusions (23 3 3 5 69) were included
in constructing this CMA.
On hematoxylin and eosin (H & E) stain, visual
estimated percentage of tumor cells on 3 cores and
original cell block sections were recorded and com-
pared. The percentage of tumor cells in proportion
to all cells on the core was estimated by visual obser-
vation of 10 randomly selected high power fields in
the cell block from the vicinity where the cores were
taken. For CMA, the estimated percentages of tumor
cells in each case were averaged from 3 cores
obtained by examination of all CMA cores at high
power view (2003 magnification). However, in cases
where there were only 1 or 2 cores left, the average
numbers were obtained by dividing the total by 1 or
2 instead of 3. Commonly used antibodies (Table 1),
staining cytoplasm (cytokeratin [CK] AE1/AE3,
epithelial membrane antigen [EMA]), and nuclei (Ki-
67) were applied to all of the original cell block sec-
tions and CMA according to established protocol and
conditions. Selected antibodies that are useful in dif-
ferential diagnosis of each primary cancer were also
included: estrogen receptor (ER), progesterone recep-
tor (PR), CK7, CK20, for breast cancer; thyroid tran-
scription factor-1 (TTF-1), CK7, CK20, for lung
cancer; CK20, CK7 for GI tract cancer; and WT-1 for
ovarian cancer (Table 1). Stain pattern and percen-
tages of positively immunostained tumor cells on
original cell block slides and on CMA were recorded
for comparison. Cytoplasmic stain by AE1/AE3, CK7,
and CK20 were considered positive patterns, whereas
cytoplasmic and membranous stains for EMA and
nuclear stain for Ki-67, ER, PR, TTF-1, and WT-1
were considered positive patterns. Stain intensity was
recorded as negative (2) or positive (weak, 11; mod-
erate, 12; and strong, 13), and the percentage of tu-
mor cells that were positive were also recorded.
RESULTS
A total of 23 tumor samples from effusions with pri-
mary tumor of breast (5), lung (5), ovary (8), and GI
tract (5, including esophageal and pancreatic) were
TABLE 2
Comparison Between Original Cell Block and CMA for Tumor Cell, and Number of Cores Present at Different
Levels
Case No. Site
% Estimated Tumor Cells *Cores on Deeper Sections
Original CB 1st CMA Section 45th Section #15 #30 #45
1 Breast 60 60 60
2 Breast 80 80 80
3 Breast 30 30 30
4 Breast 90 90 90
5 Breast 30 30 30
6 Lung 5-10 5-10 5 2
7 Lung 80 80 80
8 Lung 5-10 5-10 5
9 Lung 90 90 90
10 Lung 90 90 90
11 Ovary 50 50 50
12 Ovary 5-10 5-10 5 2
13 Ovary 40 40 40
14 Ovary 70 70 70
15 Ovary 25 25 25
16 Ovary 40 40 40
17 Ovary 90 90 70 2 2 2
18 Ovary 90 90 90
19 GI tract 10 10 10
20 GI tract 10 5-10 5
21 GI tract 20 20 20
22 GI tract 10 10 10
23 GI tract 15 15 0 2 0 0
CB indicates cell block.
*Numbers of cores on all others not indicated were 3. #15, #30, and #45 indicate deeper sections 15, 30, and 45 from the original cut.
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FIGURE 2. Representative images of each immunostain of cell blocks and their corresponding CMA cores are shown. Images labeled A-I are from cell blocks,
whereas the ones labeled A0-I0 are from CMA cores. A-A0: AE1/AE3; B-B0: EMA; C-C0: Ki67; D-D0: CK7; E-E0:CK20; F-F0: ER; G-G0: PR; H-H0: TTF-1; I-I0: WT-1
(Original magnification, 3200).
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used to construct the CMA. The proportion of tumor
cells in the original block and the subsequent cores
on CMA were similar (ranging from 5% to 90%, Fig. 1
and Table 2). In the majority of cases, although tu-
mor cells were found in all cases when counting all 3
cores, 1 or 2 cores did not have tumor cells in 4
cases that had a low tumor-cell burden (10%) in
the original cell block (Fig. 1, top left core with no
cells). To determine the potential usefulness of using
CMA for multiple marker testing, tumor cell compo-
sition at a deeper section of CMA (Section 45) was
compared with the original section and the first sec-
tion of CMA. At deeper Section 45, all cases except 1
(This case was exhausted by Section 30.) had at least
2 cores, and 19 cases still had all 3 cores present, all
having a percentage of tumor cells similar to that of
the original cell block sections (Table 2).
AE1/AE3 antibody stained all 23 cases (Fig. 1,
bottom 2 rows) on core biopsy (CB) (Fig. 2A0) and
CMA stained 21 strongly and 2 moderately (Fig. 2A,
and Table 3). EMA antibody stained 21 cases strongly
or moderately (Table 3, Fig. 2B and B0) while the
other 2 cases had only rare tumor cells on the core
to compare with the original cell block section and
thus were not included. Immunostains of AE1/AE3
and EMA were mostly strongly positive (rare cases
moderately positive) in CMA and showed 100% con-
cordance between the originals and their corre-
sponding cores on CMA regarding intensity and high
percentage of positive tumor cells (Table 3). Ki-67
antibody stained 16 cases similarly between the ori-
ginal block section and CMA (11 cases strong, 3
cases moderate, and 2 cases weak; Fig. 2C and C0),
while 3 cases scored differently. Four cases with no
tumor cells present or with rare tumor cells were not
stained for scoring (Table 3). Therefore, Ki-67 anti-
body showed somewhat lower concordance (84%, 16
of 19 cases). Excluded were the 4 cases where there
was either low tumor burden because the tumor cells
were less than 10% in original sections and there
were no tumor cells in CMA, or because only rare tu-
mor cells were present but not stained in CMA.
Similarly, although CK7, CK20, ER, PR, TTF-1,
and WT-1 were only tested for selected cases, they
stained both original sections (Fig. 2D-I) and CMA
(Fig. 2D0-I0) with a high level of agreement (Table 4).
The tumor cells stained from negative (less than 5%
tumor cell stained) to positive (more than 5% and up
to 100% tumor cells stained), and the overall staining
pattern (cytoplasmic for CK7, CK20, or nuclear for
ER, PR, TTF-1, and WT-1) and intensity of the origi-
nal blocks were recapitulated by CMA cores.
DISCUSSION
TMA allows more rapid validation of multiple immu-
nohistochemical markers than the conventional indi-
vidual case-based method.2 There have been reports
using bone marrow biopsy material, fine-needle
aspiration, and cell block material for array construc-
tion,9-11 but multiple marker validation study using
CMA from effusions has not been performed.9 This
study used 3 cores, each 0.6 mm in diameter, from
effusion cell blocks of different primary tumors to
construct a CMA. It showed that CMA was represen-
tative of the original cell blocks with tumor cell com-
position at deeper sections (to Section 45), and that
immunostaining pattern, intensity, and percentage
were similar to that of the original section for antibo-
dies tested. Concordance was high, from 84% for Ki-
67 to 100% for AE1/AE3 and EMA. There were rare
cases where low tumor burden in the original block
coupled with low percentage of staining by an anti-
body (mostly noticeable in Ki-67 staining) resulted in
slightly lower concordance. In this study, CMA was
constructed from cell blocks made by methods simi-
lar to surgical pathology specimens (fixation with
10% buffered formalin solution). However, for cytolo-
gical specimens which have been processed differ-
ently (fixation by alcohol or methanol), additional
testing is needed before accepting CMA as a routine
marker testing tool because it is known that other
fixations might not be optimal for detection of some
TABLE 3
High Concordance Between CMA and Original Cell Block on Stains
With 3 Antibodies Applied to All Samples
CMA
Cell Block Sections












Negative (\5%) 2* 2*
Weak (5-15%) 2y 1
Moderate (15-30%) 3y 2
Strong ([30%) 11y
CMA indicates cytology microarray; AE1/AE3, cytokeratin; EMA, epithelial membrane antigen.
*Indicates rare or no tumor cells to score on CMA.
yIndicates cases with agreement between the CMA and original sections.
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markers, such as ER and PR.12,13 In the authors’ ex-
perience, however, different thrombin clot cell block
methods (fixation in 10% formalin) with or without
specimens first being fixed in a methanol-based fixa-
tive such as CytoLyt (Cytyc Corporation, Malborough,
Mass) have similar immunostain profiles in several
markers tested, including ER and PR (C.W. Michael,
unpublished data).
In this study, the 3 cores in CMA were represen-
tative of the original CB in the majority of cases.
Only in rare instances did all 3 cores have no tumor
cells or low tumor cells that were not stained for pur-
pose of scoring. The necessity of using multiple cores
in TMA has been demonstrated in reducing the non-
concordance rate. In one study, nonconcordance rate
was 9.4% for single core, 4.4% for 2 cores, and 3.7%
for 3 cores.2 In some reports, single-core TMA has
been shown to have rather satisfactory reliability
(95%-98% concordance with whole tissue section) in
detecting protein expression and gene amplification
in breast cancer.3,14 Because cell blocks from effu-
sions and other cytological samples tend to have
smaller tissue fragments or cell clusters than a histo-
logical sample, a loss of 1 to 3 cores in rare cases
and no tumor cells in 1 of the 3 cores in the deeper
section in a few others was observed, arguing for
using 3 cores in constructing a CMA to increase its
representation of the original material.
In addition, although only 9 commonly used
antibodies were tested, the estimated cost associated
with constructing the CMA and staining 9 CMA
slides is less than $1000, with the majority of the
cost incurred in constructing CMA (from $400 to
$800 depending on the type of array and institution),
while the cost of staining with 9 antibodies is much
less ($250; approximately $25 per stain 39). It
translated into a saving of more than 50% when
compared with the cost of testing all 9 antibodies on
original cell block sections ($2500, $25 3ap-
proximately 120 sections). Additional marker testing
using this CMA would lead to more cost savings in
research or clinical operations.
In conclusion, although a pilot study, it is
demonstrated here for the first time that CMA is a
reliable method for validating immunocytochemical
markers in research or clinical laboratories. CMA can
represent the original cell block material accurately
in tumor cell composition and in testing of com-
monly used antibodies in staining of cytoplasm,
membrane, and nuclei. Therefore, it could be easily
deployed in either research or clinical laboratories
for a rapid marker validation. Although the initial
construction of CMA is neither simple nor inexpen-
sive, the potential for high-volume testing makes it
cost efficient despite the initial costs associated with
a CMA construction.
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